Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Melanoma is a kind of skin cancer that starts from melanocytes, which are pigment cells. It is produced by excessive Ultraviolet (UV) light exposure, which causes sunburn, especially at high elevations. Melanoma is categorized into three types: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in the treatment and increase survival rates. Melanoma is getting increasingly common and has spread to other parts of the body, according to the American Academy of Dermatology. Treatment becomes much more difficult as it spreads to other sections of the body. The rare genetic conditions such as xeroderma pigmentosum also increase the risk of melanoma and it is diagnosed with the biopsy of any skin lesion.

The global metastatic melanoma therapeutics market is estimated to be US$ 6,432.3 million in 2021 and is expected to reach US$ 13,828.9 million by 2028, at a CAGR of 11.6% during the forecast period (2021 –2028).

Figure1. Global Metastatic Melanoma Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017 - 2028

Metastatic Melanoma Therapeutics  | Coherent Market Insights

Development of new biologics is expected to drive the market growth over the forecast period.

The key players in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, as a collaborative project aimed at facilitating new drug development through collaborations. In addition, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy medications for the immuno-oncology market.

request-sample

Metastatic Melanoma Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 6,432.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 11.6% 2028 Value Projection: US$ 13,828.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Therapy: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery
  • By Stages: Stage 0, Stage I, Stage II, Stage III, Stage IV
  • By End User: Hospitals, Specialty Clinics, Home Healthcare, Others
Companies covered:

Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.

Growth Drivers:
  • Development of new biologics
  • Rising incidence of melanoma cases 
  • Technological advancements in treatment of metastatic melanoma
Restraints & Challenges:
  • Lack of awareness in some developing regions 
  • High cost associated with the therapy

Global Metastatic Melanoma Therapeutics Market – Regional Analysis:

North America holds a dominant share of the market owing to the rising incidence of melanoma and other skin cancers cases in the region. For instance, according to the Skin Cancer Foundation, skin cancer affects one out of every five Americans at some point in their lives. Furthermore, the American Cancer Society recorded 91,270 new instances of melanoma in the U.S. alone in 2018. These figures emphasize the need for new medications to aid in the treatment of melanoma in the coming years.

The U.S. government's favorable reimbursement policies aided in the development of treatment options for melanoma illnesses in an attempt to meet unmet patient requirements. This is expected to give the North American market a solid foundation for expansion. Furthermore, the presence of numerous new players is expected to drive the overall market.

Figure 2. Global Metastatic Melanoma Therapeutics Market Share (%), by End User, 2021

Metastatic Melanoma Therapeutics  | Coherent Market Insights

Global Metastatic Melanoma Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 02, 2021, are approximately 198,234,951 with around 4,227,359 deaths. Moreover, Coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the metastatic melanoma therapeutics businesses of various companies as COVID-19 pandemic has led to unprecedented lockdown in several countries, globally. This lockdown has resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the products. Thus, COVID-19 pandemic has affected the economy by directly affecting the production and demand, by creating disruptions in distribution channels and also by its financial impact on firms and financial markets.

Global Metastatic Melanoma Therapeutics Market: Restraint

The major factors that hinder growth of the Global Metastatic Melanoma Therapeutics Market include lack of awareness in some developing regions and high cost associated with the therapy. For instance, according to a report in the Journal of the National Cancer Institute, the cost of melanoma treatment was approximately US$ 2.36 billion in 2010 which increased to US$ 3.16 billion in 2020.

Key Players

Major players operating in the Global Metastatic Melanoma Therapeutics Market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.

Melanoma is a severe form of cancer, commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, are the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to Ultraviolet (UV) radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.

Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.

Market Dynamics

High incidence of melanoma leading to large patient pool is one major factor driving the global metastatic melanoma therapeutics market growth. Melanoma of the skin is the 19th most prevalent cancer in both men and women, according to the World Cancer Research Fund. Globally, the number of cases reported were nearly 300,000 new cases in 2018, which will boost the growth of global metastatic melanoma therapeutics market.

Key features of the study:

  • This report provides in-depth analysis of the global metastatic melanoma therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the metastatic melanoma therapeutics market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global metastatic melanoma therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the metastatic melanoma therapeutics market

Detailed Segmentation:

  • Global Metastatic melanoma therapeutics Market, By Therapy:
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Surgery
  • Global Metastatic melanoma therapeutics Market, By Stages:
    • Stage 0
    • Stage I
    • Stage II
    • Stage III
    • Stage IV
  • Global Metastatic melanoma therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Home Healthcare
    • Others
  • Global Metastatic melanoma therapeutics Market, By Region:        
    • North America
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy
        • Chemotherapy
        • Immunotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Surgery
      • By Stages
        • Stage 0
        • Stage I
        • Stage II
        • Stage III
        • Stage IV
      • By End User
        • Hospitals
        • Specialty Clinics
        • Home Healthcare
        • Others
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bristol-Myers Squibb Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
    • Merck & Co., Inc.
    • Genentech Inc.
    • Hoffmann-La Roche AG.
    • Amgen Inc.
    • AstraZeneca
    • Daiichi Sankyo Company, Limited.
    • AB Sciences.
    • AgonOX, Inc.
    • Eisai Co., Ltd
    • GlaxoSmithKline, plc.
    • Pfizer, Inc.
    • Vical, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Therapy
      • Market Snapshot, By Stages
      • Market Snapshot, By End User
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Global Metastatic Melanoma Therapeutics Market Insights
      • Drivers
      • Restraints
      • Opportunity
      • Impact Analysis
      • Pipeline Analysis
      • Market Trends
    • Recent Product Approvals/ Launch
      • Key Developments
      • Regulatory Scenario
      • Collaborations & Acquisitions
      • Epidemiology
      • PEST Analysis
  4. Global Metastatic Melanoma Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact of COVID-19 on demand and supply chain
  5. Global Metastatic Melanoma Therapeutics Market, By Therapy, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Radiation Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Surgery
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  6. Global Metastatic Melanoma Therapeutics Market, By Stages, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Stage 0
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Stage I
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Stage II
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Stage III
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Stage IV
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  7. Global Metastatic Melanoma Therapeutics Market, By End User, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million
    • Home Healthcare
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  8. Global Metastatic Melanoma Therapeutics Market, By Region, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Region at Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017–2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Snapshot
    • Company Profiles
      • Bristol-Myers Squibb Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Genentech Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Hoffmann-La Roche AG.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Amgen Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AstraZeneca
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Daiichi Sankyo Company, Limited.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AB Sciences.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AgonOX, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Eisai Co., Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • GlaxoSmithKline, plc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Vical, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 36 figures on "Global Metastatic Melanoma Therapeutics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global metastatic melanoma therapeutics market size is estimated to be valued at US$ 6432.3 million in 2021 and is expected to exhibit a CAGR of 11.6% between 2021 and 2028.
Development of new biologics, rising incidence of melanoma cases, and technological advancements in treatment of metastatic melanoma are fuelling the growth of market.
The immunotherapy segment is the leading therapy segment in the market.
Lack of awareness in some developing regions and high cost associated with the therapy are the major factors restraining growth of the market.
Major players operating in the market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.